Interview with Patricia Lanssiers, Managing Director, Eli Lilly BeLux
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
Address: Rue de lEtuve 52 bte 1 1000 Brussels Belgium
Tel: +32 (0)2 548 84 84
Web: http://www.lilly.be/Nitro/
Eli Lilly is a specialty pharmaceutical company entirely dedicated to innovation. Today, we are developing drugs in the first or best in class.
Our main task is to meet the needs of patients. To this end, we discover and design drugs at the forefront of their therapeutic area and we disseminate information on health, in order to solve health problems which are often difficult and complex.
Our research and development is mainly in the following therapeutic areas:
Oncology
Endocrinology
Central nervous system
Cardiovascular
Urology
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the…
Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Francis Arickx, country coordinator of Belgium for the Beneluxa Initiative, introduces the project and its mission to help shape a unified healthcare policy approach between its member countries through activities…
Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the…
Luc Van Gorp of the Christian Mutuality Health Insurance Fund, Belgium’s largest health insurance fund, explains the organisation’s role within the Belgian healthcare system, how increased consolidation in recent years…
Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration. In…
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as…
Roxana Botea, country manager of ViiV Healthcare in Belgium and Luxembourg, shares her experience joining the organization after a long career experience with GSK and her priorities as a first-time…
See our Cookie Privacy Policy Here
